
Tarsus Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
Tarsus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tarsus Pharmaceuticals Inc
Access all reports
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel therapeutic candidates targeted at various ophthalmic conditions. Its leading product candidate, TP-03, is a novel therapy aimed at treating blepharitis caused by the infestation of Demodex mites and is also being developed to address meibomian gland disease. Furthermore, the company is working on TP-04 for the treatment of rosacea and TP-05, an oral tablet intended for the prevention of Lyme disease and community malaria reduction. Tarsus Pharmaceuticals Inc. is headquartered in Irvine, California, and its shares are listed on the Nasdaq.
Key slides for Tarsus Pharmaceuticals Inc


Investor Update
Tarsus Pharmaceuticals Inc


Investor Update
Tarsus Pharmaceuticals Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TARS
Country
🇺🇸 United States